Introduction {#sec1-1}
============

Over the past two decades, many studies have been published on the effects of ketamine for postoperative pain. Several meta-analyses focusing on acute pain, perioperative pain in general, and thoracic pain in particular that have been published on this subject have concluded that low-dose intravenous ketamine infusions (LDKIs) during the postoperative period may help to relieve acute and chronic pain after major surgery, reduce the consumption of narcotics with only minimal sides effects.\[[@ref1][@ref2][@ref3][@ref4][@ref5][@ref6]\] Similarly, several randomized controlled trials (RCTs) have also noted decreased opioid consumption, decreased adverse effects as well as improved pain scores and satisfaction with LDKI.\[[@ref7][@ref8][@ref9]\] In cardiac surgery and the cardiac Intensive Care Unit (ICU), only one review has focused specifically on ketamine, without truly addressing its use for pain management.\[[@ref10]\]

Hypothesis {#sec2-1}
----------

We hypothesized that patients receiving ketamine in the postoperative period would consume less opioids and would have less chronic pain following cardiac surgery. Therefore, in our cardiac surgery specialized care center, some anesthesiologists used a low-dose ketamine infusion for all consecutive patients to whom they provided anesthesia with the intent of decreasing perioperative opioid consumption and the prevalence of postoperative chronic pain. This paper presents the results obtained and lessons learned from LDKI.

Methods {#sec1-2}
=======

This case--control study combines a retrospective review of prospectively collected data and a prospective evaluation of chronic pain after surgery. Administrative and Ethics Committee approval was obtained: ICM-2011-1274.

Cases were defined as all patients \>18 years of age, who had cardiac surgery involving a median sternotomy and who received an infusion of ketamine on arrival in the ICU. Controls were age-, sex-, and surgery-matched patients who did not receive a ketamine infusion (−LDKI) in the postoperative period. The exclusion criteria included all patients for whom the standard extubation protocol was not applied and all patients in the nonketamine group who received enteral ketamine as an adjuvant pain medication in the postoperative period.

All patients, in both groups, received induction and maintenance anesthesia at the anesthesiologist\'s discretion and were administered the standard postoperative pain protocol, adjusted for individual needs by the acute pain team on a daily basis. LDKIs were prepared using 100 mg of ketamine in 100 ml of normal saline and infused at a rate between 50 and 200 mcg/kg/h for a maximum of 2 days.

Patients were contacted by phone between 6 and 13 months after their surgery by a research assistant to evaluate the prevalence of pain at the time of discharge (yes/no) and prevalence of surgery-related pain during the last 24 h (yes/no).

Descriptive results are presented as means ± standard deviations for continuous variables and as frequencies (percentages) for categorical variables. Comparisons of demographics and clinical data at baseline were based on Student\'s *t*-tests for continuous variables and on Pearson\'s Chi-square statistics for categorical variables. The primary endpoint (pain postsurgery) was compared between groups. Statistical analysis was completed using SAS version 9.2 by the Montreal Health Innovations Coordinating Center.

Results {#sec1-3}
=======

A total of 230 patients were included in the study, 115 who received low-dose postoperative ketamine (+LDKI) and 115 who did not receive low-dose postoperative ketamine (−LDKI). Follow-up response rates were 94.4% and 88.8% respectively for the ketamine and nonketamine groups. Descriptive analysis showed that there were no differences between the groups in terms of age, gender, weight, height, body mass index, American Society of Anesthesiologists status, type or length the surgery, and cardiac bypass time \[Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}\].

###### 

Descriptive statistics of the study population for the (+LDKI) and (-LDKI) groups

                              Ketamine     Non-Ketamine   *P*
  --------------------------- ------------ -------------- -------
  Number of patients          115          115            1,0
  Percent Male (*n*)          73,04 (84)   73,04 (84)     1,0
  Mean Age (years)            63,1         63,0           0,925
  Mean Weight (kg)            82,2         80,1           0,372
  Mean Height (m)             1,7          1,7            0,899
  Mean BMI (kg/m^2^)          29,0         28,3           0,437
  Type of Surgery % (*n*)                                 
   CABG                       51,30 (59)   52,17 (60)     NS
   Valve replacement          20,87 (24)   24,35 (28)     NS
   CABG + valve replacement   13,04 (15)   11,30 (13)     NS
   Complex surgery            14,78 (17)   12,17 (14)     NS

###### 

Intraoperative Information for the + LDKI and the -LDKI Groups

                                                      Kétamine   Non Ketamine   *P*
  --------------------------------------------------- ---------- -------------- -------
  Mean length of surgery (hours)                      4,76       4,85           0,566
  Mean length of cardiac bypass (hours)               1,37       1,37           0,984
  Percent of patients with ASA score ≥4               45,2       44,7           0,942
  Percent of patients with a grade of intubation ≥3   2,73       7,48           0,072

The average duration of the infusion was 26.8 h, the average dose was 169.9 mg, and the mean +LDKI dose in mcg/kg/h was 86.2 \[[Table 3](#T3){ref-type="table"}\]. Infusion of ketamine did not affect the length of intubation, the length of ICU or hospital stay but did show that patients required more opioid (morphine equivalents) in milligrams per kilogram before extubation \[[Table 4](#T4){ref-type="table"}\]. [Table 5](#T5){ref-type="table"} presents intraoperative medications for both groups and [Table 6](#T6){ref-type="table"} presents postoperative opioid consumption, in morphine equivalents, showing a slightly higher postoperative consumption of opioids in the ketamine group.

###### 

Characteristics of + LDKI group

                                              Kétamine
  ------------------------------------------- ----------
  Mean length + LDKI (hours)                  26,8
  Mean total dose of ketamine received (mg)   169,9
  Mean + LDKI doses in mcg/kg/hours           86,2

###### 

Length of intubation, length of ICU and hospital stay and postoperative morphine consumption for the + LDKI and -LDKI groups

                                            Ketamine   Non Ketamine   *P*
  ----------------------------------------- ---------- -------------- -------
  Length of intubation (hours)              9,69       8,60           0,079
  MS Equiv^1^ prior to extubation (mg/kg)   0,39       0,29           0,005
  Length of ICU stay (hours)                51,76      57,95          0.54
  Length of hospital stay (days)            6,98       7,54           0,276

^1^IV: Morphine Equivalents

###### 

Mean Doses of Medications for the + LDKI and -LDKI groups

  Type of Medication                     Ketamine   Non Ketamine   *P*
  -------------------------------------- ---------- -------------- ----------
  Intraoperative MS Equiv^1^ (mg)        299,0      248,3          \<0 ,001
  Intraoperative MS Equiv^1^ (mg/kg/h)   8145       651,3          \<0 ,001
  Intraoperative Ketamine (mg)           57,9       41,8           \<0 ,001
  Intraoperative Magnesium (mg)          3195,9     2596,9         0,06
  Preoperative Gabapentin (mg)           507,0      370,4          0,019
  Preoperative Acetaminophen (mg)        761,3      469,0          \<0 ,001

^1^ MS: IV Morphine Equivalents

###### 

Postoperative Narcotic Consumption (mg/kg/day) on days 0 to 4

  Postoperative Day           Ketamine   Non Ketamine   *P*
  --------------------------- ---------- -------------- -------
  MS Equiv^1^ Day 0 (mg/kg)   0,42       0,38           0,053
  MS Equiv^1^ Day 1 (mg/kg)   0,49       0,42           0,004
  MS Equiv^1^ Day 2 (mg/kg)   0,29       0,26           0,055
  MS Equiv^1^ Day 3 (mg/kg)   0,11       0,08           0,023
  MS Equiv^1^ Day 4 (mg/kg)   0,08       0,04           0.027

^1^ IV: Morphine Equivalents

At follow-up, an average of 9 months after surgery, 47.8% of the (+LDKI) group and 44.6% of the (−LDKI) group stated that they had had pain on discharge. Of these patients, 37% of the (+LDKI) group and 33% of the (−LDKI) group still had pain at the time of the phone call \[Tables [7](#T7){ref-type="table"} and [8](#T8){ref-type="table"}\]. Neither of these differences was statically significant. However, a significantly higher proportion of women in both the (+LDKI) and (−LDKI) group complained of pain on discharge and chronic pain, at the time of the phone call \[Tables [7](#T7){ref-type="table"} and [8](#T8){ref-type="table"}\].

###### 

Proportion of patients in the -LDKI group who had pain at discharge and at the time of phone call

  Demographics   Pain at discharge %   Pain at time of phone call %   Pain on discharge/pain at average 9 months post surgery %
  -------------- --------------------- ------------------------------ -----------------------------------------------------------
  Males          33.8                  26.4                           78.1
  Females        70.0                  48.3                           69.0
  Total          43.6                  32.7                           75.0

###### 

Proportion of patients in the+LDKI group who had pain at discharge and at the time of phone call

  Demographics   Pain at discharge %   Pain at time of phone call %   Pain on discharge/pain at average 9 months post surgery %
  -------------- --------------------- ------------------------------ -----------------------------------------------------------
  Males          40.7                  32.1                           78.8
  Females        67.9                  46.4                           68.3
  Total          47.7                  35.8                           75

Discussion {#sec1-4}
==========

This case--control study evaluates the prevalence of chronic pain at an average of 9 months' postcardiac surgery in two groups of patients: Those who received ketamine and those who did not. The results do not demonstrate that ketamine infusion decreased the level of opioid consumption nor chronic postoperative pain. Ketamine infusions did not result in a lower proportion of patients complaining of pain between 6 and 12 months after surgery, nor did it have an impact at the time of discharge as patients in the ketamine group recalled slightly higher levels of pain at the time of discharge than those who did not receive ketamine. What is compelling, however, is that women report pain at discharge (approximately, 65% in both groups) and long-term (approximately 50% in both groups) than men. This difference is statistically significant.

It is interesting to note that although most published RCT\'s and meta-analysis studies, including those referenced above, show a modest positive effect for ketamine as a perioperative analgesic none have evaluated the influence of ketamine on the prevalence of chronic pain. This study provides evidence in real-life anesthesia that a postoperative ketamine infusion was not effective in decreasing chronic pain after cardiac surgery. This real-world effectiveness study is the first to evaluate the potential long-term benefits of ketamine for decreasing chronic postoperative pain after cardiac surgery.

Of note is that narcotic consumption in the postoperative period was significantly higher in the +LDKI group. This may be because anesthesiologists who administered an LDKI postoperatively also tended to use higher doses of intraoperative opioid when compared to all comers in the non-LDKI group. This raises the question of whether or not hyperalgesia or some other postoperative pain protocol factor could be a contributing to the higher doses of narcotics seen postoperatively in the +LDKI group. Although some studies have indicated that high dose opioids are a factor in postoperative hyperalgesia most implicate remifentanil. Few human data are available with respect to more long-acting opioids.\[[@ref11]\]

This study demonstrates the effectiveness, as opposed to the efficacy, of a systematically applied technique in a real-world clinical situation.\[[@ref12]\] Evaluation of the data showed that the technique was not effective in decreasing postoperative pain and consequently led the investigators to cease application of the technique. One hypothesis for these results is that the lack of postoperative effectiveness may have been related to the fact that both groups received intraoperative ketamine. An intraoperative dose of ketamine may be all that is required to provide a decrease in postoperative pain and adding a continuous infusion provides no added benefit.

One weakness of this study is the lack of prospective data for pain scores at discharge as it is possible that there is a recall bias related to the level of pain experienced by patients after surgery. This is somewhat tempered by prospectively collected chronic pain scores.

Conclusion {#sec1-5}
==========

In a real-world, effectiveness study, low-dose intravenous ketamine (+LDKI) for post cardiac surgery pain did not result in a decreased incidence of chronic pain. A significantly large number of patients, women, in particular, are at high risk for long-term pain after cardiac surgery. Measures such as daily individualized patient care plan closely monitored and tailored analgesic regimens and special attention to women undergoing surgery need to be implemented to decrease the burden chronic pain after cardiac surgery.
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